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Background: Women who undergo a cesarean section (CS) are in a unique position to receive 
the intrauterine contraceptive device (IUD). They may also want to use the IUD as a long-
acting reversible contraceptive method provided the IUD is safe and effective in the presence 
of a CS scar.
Search strategy: We researched and reviewed the MEDLINE, POPLINE, Google Scholar, 
and ClinicalTrials.gov databases from January 1968 to June 2015.
Selection criteria: Eligible studies reported event rates or practical problems relating to IUD 
usage in post-placental or interval insertion (.90 days) after CS. Studies with 20 subjects 
were included.
Data collection and analysis: Analysis of eligible data collected from the search followed 
the PRISMA guidelines.
Main results: Twelve eligible studies of post-placental IUD insertion after CS included four 
randomized controlled trials of post-placental versus delayed insertion. Women randomized 
to delayed insertion were less likely to receive a device. Six studies examined the problem of 
missing IUD threads at follow-up with only 30%–60% presence of strings observed.
Conclusion: The IUD is a long-acting reversible contraceptive method that is suitable for use 
in all women undergoing CS. The problems of device expulsion, missing threads at follow-up, 
and the tendency of increased puerperal bleeding need to be solved. Solutions are proposed.
Keywords: post-placental IUD, cesarean section, missing IUD threads, IUD expulsion, long-
acting reversible contraception
Introduction
LARC is the most clinically and economically effective type of contraception.1,2 
Implants and IUDs have a rapid action of onset after administration with a rapid 
return to fertility after discontinuation.3,4 LARC methods are therefore ideally suited 
to play a major role in fertility regulation worldwide as well as in Global South (GS) 
or impoverished countries.
CS rates are rising in all countries, including those of the GS.5 IUD insertion at the 
time of CS creates an opportunity to increase access to LARC methods. Conversely, a 
previous CS scar may deter access to interval insertion of an IUD if a previous CS may 
result in difficulty with insertion and/or future IUD problems. We updated a previous 
systematic review6 to see if post-placental and interval IUD insertion could be made 
more accessible for women wanting to use this method.
Even though it has only been a few years since our initial review, there have been a 
number of new detailed studies in this area.7–21 The later, newer studies are constructed 
and some are controlled so that we are able to get a better understanding of how best 
to utilize the post-placental CS opportunity, and how to deal with the CS scar in those 
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women who want an IUD after having previously had a CS. 
This review updates our previous analysis of insertion of 
IUDs in women who have had a CS and where IUD insertion 
has been post-placental or interval.
Methods
This study is a systematic review to evaluate complications 
and performance after an IUD is inserted into women who 
have had a CS. There are two main categories: 1) inser-
tion at the time of CS, ie, PPIUDCS and 2) interval inser-
tion6 (42 days or more after CS [IIUDCS]).
In more recent studies this distinction may have become 
slightly blurred since the newer studies have subjects in both 
groups ie, post-partum and very early interval, as they are 
controlled and compare post-placental insertion with 6- to 
8-week post-partum insertion as a control group.12,13 The 
control group thus “straddles” the boundary of post-partum 
and interval6 insertion. We will consider these as interval 
insertions (IIUDCS) as opposed to post-placental insertions, 
since post-placental insertions are defined by being able to 
place the device in the uterine cavity under direct vision, the 
only time it is possible to do this. The straddled insertions 
at 6–12 weeks post-partum have been added to the to the 
IIUDCS group.
The methods used for data collection have been described 
in the previous study6 and included both controlled and uncon-
trolled studies, but were modified as described in the follow-
ing section. The reference list for this study was generated 
from searching for references from the following databases: 
MEDLINE: “Intrauterine device (IUD, IUCD)”/“Intrauterine 
system (IUS) [MeSH]” AND “Cesarean section, caesar-
ean section CS, C/S [MeSH]”. “Intrauterine device (IUD, 
IUCD)”/“Intrauterine system (IUS)”. POPLINE: “IUD” AND 
“cesarean section”. PubMed: “IUD” AND “cesarean section”. 
Google Scholar: “IUD”, “IUS” AND “post-placental cesarean 
section”, AND “IUD” AND “interval cesarean section”, the 
terms were filtered so as not to overlap in the advanced search. 
ClinicalTrials.gov: “intrauterine device” AND “cesarean 
section”. We did not search Wangfang Data and Weipu 
Data. Significant Chinese articles are beginning to appear in 
English language databases. Our study updates peer-reviewed 
papers from January 1968 to December 2012, which formed 
the basis of the previous report. In that study we searched for 
references from January 1968 to December 2012. The current 
search was divided into two parts: 1) to see if new references 
(especially foreign language) were added to the databases 
during that period (January 1968 to December 2012); and 
2) to do an updated search from December 2012 to June 2015. 
This latter search is the main focus of this report.
The inclusion criteria for selection of studies were 
broadened. Previously, we only included studies that con-
tained principal event rates (pregnancy, expulsion, medical 
removal, and continuation rate) in at least 20 subjects. In 
this study we have included clinical complications such as 
pain, bleeding, discomfort, missing strings, and any other 
adverse reports in studies of 20 subjects. The systematic 
review section was conducted following the PRISMA 
guidelines,22 a flow chart of selection of articles from 
January 2013 to June 2015 is given in Figure 1. We did not 
search the Chinese databases, but we actively searched for 
non-English articles that are increasingly being added to cur-
rent databases, especially POPLINE. Higher weighting was 
given to RCTs and those with higher degrees of evidence, 
as indicated in the PRISMA guidelines.22 These types of 
studies are now more common, as interest is growing in 
this area. We found two Chinese23,24 and one Malaysian 
study25 in the PPIUDCS group prior to December 2012, and 
one Chinese study in the IIUDCS group. The January 2013 
to June 2015 search produced 12 papers in the PPIUDCS 
group, and two in the IIUDCS group. The selection process 
is given in Figure 1.
The previously missing references were found by repeat-
ing the POPLINE search, which found the new references that 
had been added by POPLINE to their database in the interim. 
These references have been added to our earlier database, 
and the table of post-partum CS insertion from our earlier 
paper has been updated (Table 1). Summary odds ratios were 
not computed because of the highly nonhomogeneous data 
reporting methods.
Results
The search of the older references added a Lippes loop 
(Ortho, Raritan, NJ, USA) study in Malaysia,25 a Chinese 
study of the GyneFix PP (Contrel Europe NV, Ghent, 
Belgium),23 and an RCT of the Fix-T-Cu 220C-M and the 
Delta T-Cu220C to the PPIUDCS group. These have been 
added to the old database of experience (January 1968 to 
December 2012) and are presented in Table 1.26–39 There was 
one IIUDCS study of the VCu200 IUD, which was a com-
parative study of subjects who had a CS versus those who 
had not had a CS at 42–90 days post-partum. This study has 
been added to the previous studies of mostly older IUDs.6 In 
the VCu200 study, there was one ectopic pregnancy (0.32%) 
and at 2-year follow-up the expulsion rate was 2.68 per 
100 woman years of use for the CS group, and 2.65 for the 
non-CS group. The pregnancy rate for the CS group was 
4.49, and 5.88 for the non-CS group per 100 woman years 
of use, as determined by life table analysis. The tendency, 
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Figure 1 Flow chart of selection of articles from December 2012 to June 2015 (PRISMA).
Abbreviation: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Table 1 Updated PPIUDCS studies published before December 2012
Event rate per 100 woman years (range)
Type of IUD Studies Subjects 
followed
Expulsion Medical 
removal
Pregnancy Comments and references
Mirena 1 33 0 0 0 12-month follow-up27
MLCu 250 1 154 2.6% 7.8% 0 12-month percentage rate28
TCu220 3 714 (1.78–10.9) Not stated 0–1.1 12-month cumulative rate29–31
TCu380A 5 314 (0–17.6) (0–10.6) 0 One study had 6-month follow-up32–36
Delta T
Delta loop
Delta Beijing
2 135 (4.1–9.6) 7.2 2.4 One reported 6-month cumulative, the 
other 24-month percentage rates37,38
GyneFix PP IUDa 1 200 4% Not stated 0 3-month percentage rates23
Fix-T-Cu 220C-Ma
Delta-TCu 220Ca
1 200
200
2.2%
10.5%
2.5%
2.6%
0.5%
0.5%
RCT at 30 months. 30-month 
cumulative life table rates24
Metal ring-catgut knots 7 3,131 (1.2–9.6) (0.8–7.2) (0–7.5) Cumulative rate from 6–24 months38,39
Lippes loopa 1 204 12.2% 3.9% 0.49% 12-month percentage rates25
Notes: aNewly added studies. Chi et al38 reported nine Chinese studies that were also reported in Chi et al37 and Liu et al.39 The data were only used once. Mirena (Bayer 
AG, Levekusen, Germany); MLCU 250 (Multilan SA, Fribourg, Switzerland); TCu220 (Population Council, New York, NY, USA); TCu380A (Teva Pharmaceuticals, Petach 
Tikva, Israel); (Delta T, Delta loop, Delta Beijing, [Chinese government, Beijing, People’s Republic of China]); Lippes loop (Ortho, Raritan, NJ, USA); GyneFix PP (Contrel 
europe Nv, Ghent, Belgium); (Fix-T-Cu 220C-M, Delta-TCu 220C, [Chinese Government, Beijing, People’s Republic of China]).
Abbreviations: PPIUDCS, post-placental IUD at CS; CS, cesarean section; IUD, intrauterine contraceptive device; RCT, randomized controlled trial.
since the end period of the last review (from 2013 onwards), 
has been a move to controlled studies of different IUDs 
with different time periods in the PPIUDCS groups. It is 
this information which can provide the “which” and the 
“when” for PPIUDCS and IIUDCS insertion, and can help 
improve clinical practice.
Ten studies from the January 2013 to June 2015 search 
met the criteria for inclusion in the PPIUDCS group, the 
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selection process is shown in Figure 1. Two studies met 
the inclusion criteria in the IIUDCS group.8,16 These two 
studies, which examined the use of interval IUD insertion 
in women who had had a previous CS, were designed to 
examine insertion problems rather than event rates. The first 
study8 evaluated pain during insertion of the LNG releasing 
IUD (LNG IUD) in 28 parous women who had undergone 
at least one CS compared with 23 nulligravid women and 
23 parous women who had not undergone CS. Nulligravid 
women experienced the most pain, followed by women with 
previous CS. The second study evaluated the use of misopros-
tol versus diclofenac before IUD insertion in women who had 
only given birth by CS. One hundred and thirty women were 
given misoprostol 400 µg sublingually and 100 mg diclofenac 
orally, while 125 were given diclofenac orally only.16 The use 
of misoprostol in addition to diclofenac did not help with the 
insertion process. Ease of insertion and pain experienced with 
the insertion was the same in both groups. Insertion failure 
rates were similar in both groups. The misoprostol group 
experienced more abdominal pain and nausea. There were 
no new studies on expulsion rates in IIUDCS insertions. Our 
previous data, showing a greater incidence of expulsion with 
older and much older devices in interval insertion in women 
with previous CS,6 cannot be updated for TCu380A (Teva 
Pharmaceutical Industries Ltd., Petach Tikva, Israel), LNG 
IUD, Nova T 380 (Bayer AG, Levekusen, Germany), and 
GyneFix PP, which are the IUDs in current use.
There were therefore a total of 12 new eligible papers 
from December 2012 to the present day search7–17,19–21 
(10 PPIUDCS and 2 IIUDCS). Our expanded inclusion criteria 
also allowed us to include two papers from the earlier search 
that did not meet the previous inclusion criteria.7,10 Both were 
studies that focused on puerperal bleeding, which is of par-
ticular relevance in low socioeconomic environments. These 
two studies have been added to the ten (PPIUDCS) from the 
later search and are presented in Table 2. There was one RCT 
of three different devices, Nova T 380, TCu380A, and MLCu 
375 (Multiload Copper375; Multilan SA, Fribourg, Switzer-
land), with significantly lower expulsion rates for the MLCu 
375.14 This RCT is the first three-way study that attempts to 
evaluate which type of IUD is superior, and not assume they 
behave generically in this situation unless they are tethered 
to the uterine fundus.20 There were four RCTs of PPIUDCS 
insertion versus interval insertion (at 4–8 weeks).12,13,15,17 All 
had small numbers and limited follow-up. They all showed 
that those allocated to the delayed insertion group very often 
failed to present for their later insertion. This was true in both 
developed countries like Australia,13 and GS countries like 
Uganda.12 One study described a new technique to anchor 
the IUD to the fundus (hang up) to prevent expulsion,20 while 
one examined elongating threads to help prevent the problem 
of missing threads.14 Expulsion rates were very variable, 
with no expulsions in studies with very small numbers13,17 
and where the device was sutured into the uterus,20 while in 
other studies it varied between 10% and 15%. There were no 
reports of perforations.
While expulsion and missing strings are important 
problems everywhere, they are of particular significance for 
situations in which ultrasound is not available, which is often 
the case in the GS. Two studies examined the effect of IUD 
type on puerperal bleeding.7,10 LNG IUD was significantly 
better in reducing puerperal blood loss which is important in 
helping to prevent anemia, and this is of major importance in 
areas where undernourishment may be prevalent, as is often 
the case in the GS.
We have analyzed reports of missing strings from those 
studies in which it has been detailed. The information that 
is available is presented in Table 3 and its importance is 
discussed later. Elongating the threads and guiding them 
through the cervix results in strings being visible in all 
cases.14,36 For IUDs that have long threads eg, ML Cu375, 
simply pushing the threads through the cervix at the time of 
CS produces a 92% visibility rate at 6 weeks and 6 months.7 
If the threads of the TCu380A are left at the incision length, 
then follow-up visibility is around 30%–40%. The same is 
true for the LNG IUD, where string visibility of 30%–60% 
was reported in two studies.13,15 The elongated strings require 
trimming at follow-up. Missing strings require that the 
presence and position of the IUD be verified by ultrasound, 
which as previously stated, is a big problem for clinics in 
GS countries. There were 70 LNG IUDs placed at 6 weeks 
post-partum after CS in three studies13,15,17 and 22 TCu380A 
IUDs.12,15 At 6-month follow-up there were seven LNG 
IUD expulsions and one expulsion in the TCu380A group. 
Losses to follow-up of around 14% were analyzed using the 
“intention to treat” method.
Discussion
The first study on the use of PPIUDCS was by Zerzavy in 
1967.40 He inserted a Birnberg Bow size 5 or 7 and sutured 
it in place at CS. After that there were relatively few studies 
over many years. The main reason for this is that IUDs were 
firmly in the shadow of the infection scare. The risks of 
the procedure appeared to override the potential benefits. 
Sporadic attempts to revive the procedure were made in the 
1970s and 1980s. This anxiety regarding PPIUDCS began 
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to dissipate in the 1990s due to the realization that the IUD 
is not primarily responsible for causing infection41 and the 
introduction of the LNG IUD/IUS (Mirena). More recently 
there has been renewed interest in LARC, because of its well 
described role in limiting unintended pregnancies.1 Inserting 
an IUD at the time of CS is a very attractive option. It adds 
very little time and cost to the procedure. The patient does 
not have to come back especially for follow-up, and there 
is no risk of primary perforation (secondary perforation is 
possible) as it is performed under direct vision. Should it 
remain in place a 5-year follow-up seems to indicate that 
it will behave similarly to interval insertion in woman with 
and without CS.14
There appears to be two early problems with PPIUDCS. 
Initial expulsion rates, although not as high as those after 
vaginal birth post-partum insertion, are still unacceptably 
high (5%–10%). This is the only time an IUD is inserted 
into the uterine cavity under direct vision, and the use of 
the correct anchor has the ability to make the expulsion rate 
close to zero.20,42,43 If a method to hold the IUD in the uterus 
is used, eg, with suturing into the uterine muscle techniques,20 
expulsion can be reduced to below 1%. This adds to the com-
plexity of the procedure, and in most cases requires additional 
training for those inserting the devices. The second problem 
of importance is missing threads. In many GS situations ultra-
sound is often not available, making this a time-consuming 
problem which often mandates referral to a tertiary center. 
Techniques for lengthening threads to ensure their pres-
ence in the vagina exist, but often necessitate trimming and 
so may require an extra post-partum follow-up. However, 
this is easier to undertake than referral for ultrasound, and 
post-partum evaluation should be conducted anyway, but 
even this can create difficulties in the GS.14,36 The problem 
of missing strings after PPIUDCS insertion is of consider-
able importance with regard to advancing this method in 
the GS. There have been various approaches to attempt 
to resolve this problem. In one study vicryl was used to 
lengthen the threads.14 The use of absorbable material which 
ensures that the strings remain visible, but subsequently 
absorb so that they are not too long, may be a solution. 
These techniques are among those which have the capacity 
to expand access in the GS and indeed worldwide.
The use of 6-week controls has created a new group of 
post-CS IUD recipients for study. While the insertion of 
IUDs at the 6-week follow-up after CS is not new, we added 
the results of insertions at 42–90 days post-CS26 and the 
6-week post-CS insertions in the newer studies. The differ-
ence between the post-CS at around 6 weeks and the truly 
interval insertions (90 days post-CS) is the risk of certain 
specialized complications, eg, perforations.44 For this reason 
we consider that this group should be examined separately 
from PPIUDCS and IIUDCS. There is as yet no study report-
ing the outcomes of insertions performed exclusively in the 
40–45 days post-CS period.
Conclusion
PPIUDCS has many practical advantages. The recipient 
can leave with the IUD in place and will be protected from 
pregnancy even if she does not attend follow-up, provided 
the IUD remains in place. Further evidence from systematic 
review of recent studies is providing us with new informa-
tion to help make this a more acceptable option for women 
Table 3 Missing strings after PPIUDCS
Study IUD Number Strings 
observed (%)
Interval after 
insertion
Comments
Zhang H et al23 GyneFix PP 200 86 6 W The device is attached to the fundus under direct vision
Nelson et al36 TCu380A 7 100 6 W Modified extended strings guided through cervix into vagina
Levi et al34 TCu380A 32 28 6 W Normal strings placed in the cervix
Lester et al12 TCu380A 27 44 6 W
Bhutta et al7 MLCu 375 50 92 and 92 6 W and 6 M Long thread of MLCu 375 pushed through the cervix
Singal et al21 TCu380A 300 61 and 84 6 W and 12 M More strings seen at 12 M follow-up
Braniff et al13 Mirena 23 31.6 6 W Strings not directed through the cervix
Levi et al15 Mirena
TCu380A
21
10
67
40
6 M
6 M
Ragab et al14 Nova T 380
MLCu 375
TCu380A
40
40
40
100
100
100
6 W and 60 W Strings lengthened with vicryl and placed through cervix 
into the vagina
Notes: Mirena (Bayer AG, Levekusen, Germany); Nova T 380 (Bayer AG); MLCu 375 (Multiload Copper375; Multilan SA, Fribourg, Switzerland); GyneFix PP (Contrel 
europe Nv, Ghent, Belgium).
Abbreviations: PPIUDCS, post-placental IUD at CS; IIUDCS, interval insertion of IUD after CS; CS, cesarean section; IUD, intrauterine contraceptive device; W, weeks; 
M, months.
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in the GS and elsewhere. In order to expand access to this 
procedure there are three main problems to be solved, 
namely: 1) prevent expulsion – whether by device design 
or suture technique; 2) ensure that strings are visible, and if 
possible do not require adjustment; and 3) reduce puerperal 
bleeding – hopefully by the use of cheaper hormone releasing 
devices, which should soon become available.
List of abbreviations
CS, cesarean section; IUD, intrauterine contraceptive device; 
LARC, long-acting reversible contraceptive; GS, global 
south; PPIUDCS, post-placental IUD at CS; RCT, random-
ized controlled trial; IIUDCS, interval insertion of IUD after 
CS; LNG, levonorgestrel.
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